Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975371 | 1.00 | HDAC6 (0.45) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL9973808 | 0.86 | HDAC6 (0.47) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL9975332 | 0.85 | HDAC6 (0.47) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL1626289 | 0.85 | HDAC6 (0.47) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL9975375 | 0.85 | HDAC6 (0.48) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL9975352 | 0.84 | HDAC6 (0.45) | HDAC6CDK1PYGMSLC5A2SLC5A1 | |
| SCHEMBL1626754 | 0.84 | HDAC6 (0.45) | HDAC6CDK1PYGMSLC5A2SLC5A1 | |
| SCHEMBL9975360 | 0.83 | HDAC6 (0.48) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL1625756 | 0.83 | HDAC6 (0.48) | HDAC6CDK1PYGMHSPA5HSPA8 | |
| SCHEMBL9975367 | 0.83 | HDAC6 (0.48) | HDAC6CDK1PYGMHSPA5HSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| US-8202844-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-21 | — | — | US | disclosed |
| US-7928080-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-19 | — | — | US | disclosed |
| US-7625871-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281052-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-12 | — | — | US | disclosed |
| US-7419963-B2 | Indole antiviral compositions and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-02 | — | — | US | disclosed |
| US-20080146517-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-06-19 | — | — | US | disclosed |
| US-20050143329-A1 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281052-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK1 232/4885PYGM 523/4885 |
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK1 232/4885PYGM 523/4885 |
| US-20080146517-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK1 232/4885PYGM 523/4885 |
| US-20050143329-A1 | Indole antiviral compositions and methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK1 232/4885PYGM 523/4885 |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK1 232/4885PYGM 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.